Takaku F
Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.
Tokai J Exp Clin Med. 1986;11 Suppl:197-204.
184 cases of aplastic anemia were treated by various immunosuppressive agents. 25.1% of the 35 patients with moderately severe aplastic anemia showed a hematological response to bolus methylprednisolone m PSL treatment. 9.6% of 73, 16.9% of 65 and 42.9% of 14 cases with severe aplastic anemia responded to m PSL, anti-lymphocyte globulin and anti-thymocyte globulin treatment, respectively. There was no difference in the survival of these severe aplastic anemia patients, however, which were prolonged invariably by treatment with each of these immunosuppressive agents. No correlation was observed between the in vitro increase of hematopoietic cell colony growth of the patient's bone marrow and clinical response to the immunosuppressive agents.
184例再生障碍性贫血患者接受了各种免疫抑制剂治疗。35例中度重型再生障碍性贫血患者中，25.1%对大剂量甲基强的松龙（mPSL）治疗有血液学反应。73例重型再生障碍性贫血患者中9.6%、65例中16.9%以及14例中42.9%分别对mPSL、抗淋巴细胞球蛋白和抗胸腺细胞球蛋白治疗有反应。然而，这些重型再生障碍性贫血患者的生存率并无差异，不过，每种免疫抑制剂治疗均能使生存率延长。未观察到患者骨髓造血细胞集落生长的体外增加与免疫抑制剂临床反应之间存在相关性。
